Massachusetts General Hospital: Carcinoma, Non-Small-Cell Lung trials

The registry lists 28 Carcinoma, Non-Small-Cell Lung studies with Massachusetts General Hospital as lead sponsor. 3 are open to participants now and 11 have results posted.

Early Phase 1 1Phase 1 4Phase 2 13No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLCRecruitingNCT07405190Phase 2
• Patient-centered, Optimal Integration of Survivorship and Palliative CareRecruitingNCT04900935Not applicable
• DNA Analysis of Blood and Tissue From Patients With Lung CancerRecruitingNCT00471978
• Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedNCT02521051Phase 1/2Results posted
• Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung CancerCompletedNCT02394548Not applicableResults posted
• A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLCCompletedNCT02314364Phase 2Results posted
• Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFRCompletedNCT01854034Phase 2Results posted
• Ponatinib in Advanced NSCLC w/ RET TranslocationsCompletedNCT01813734Phase 2Results posted
• AUY922 for Advanced ALK-positive NSCLCCompletedNCT01752400Phase 2Results posted
• Understanding Mechanisms of Acquired Resistance to BIBW2992CompletedNCT01074177Not applicableResults posted
• Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01026844Phase 1Results posted
• Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) MutationsActive, not recruitingNCT00977470Phase 2Results posted
• Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00642759Phase 2Results posted
• Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFRCompletedNCT00567359Phase 2Results posted
• Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment DiscontinuationActive, not recruitingNCT06146920Not applicable
• Immune and Genomic Markers in ALK+ NSCLCActive, not recruitingNCT04881916
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
• Supportive Care Mobile Application for Patients With NSCLCCompletedNCT04629300Not applicable
• The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to SurveillanceActive, not recruitingNCT04450043Not applicable
• Immune Checkpoint Inhibitors and Atherosclerotic Plaque VolumeCompletedNCT04430712
• A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCActive, not recruitingNCT03202940Phase 1/2
• A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial LesionsStatus unknownNCT02927340Phase 2
• Improving Care After ChemotherapyCompletedNCT01944137Not applicable
• Adjuvant Afatinib in Stage I-III NSCLC With EGFR MutationStatus unknownNCT01746251Phase 2
• Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung CancerTerminatedNCT01565772Phase 1
• Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung CancerTerminatedNCT01525446Early Phase 1
• Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT01038271Not applicable
• Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00411047Phase 2